Value of Montelukast as a potential treatment of Post COVID-19 Persistent cough: A randomized controlled pilot study

This pilot study included 68 cases with Post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups;intervention group 32 patients received standard cough therapy and Montelukast 10 mg/day for14 days and control group 36 patients received cough sedatives. We found significant improvement in number of cough paroxysms/day, cough severity visual analog scale, cough severity index and cough quality of life, shorter duration improvement and minimal side effects in interventional group. We suggest that Montelukast may be effective to reduce duration, severity of persistent Post COVID-19 cough and improve quality of life.